Evidence map›Paper›PMID 25169561›Full record

ReviewEndocrinology and metabolism clinics of North America2014

Diabetes mellitus type 2 and abnormal glucose metabolism in the setting of human immunodeficiency virus.

Colleen Hadigan, Sarah Kattakuzhy

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Endocrinology and metabolism clinics of North America, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Endocrinological aspects of HIV infection.Journal of endocrinological investigation · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Colleen HadiganLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, NIH, 10 Center Drive, Bethesda, MD 20892, USA. Electronic address: hadiganc@niaid.nih.gov.
Sarah KattakuzhyLaboratory of Immunoregulation, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, 5705 Industry Lane, Frederick, MD 21702, USA.

Funding

Intramural NIH HHS Z99 AI999999NCI NIH HHS HHSN261200800001E
6 · The paper itself

Abstract

As the modern era of combination antiretroviral therapy has increased life expectancy for individuals infected with the human immunodeficiency virus (HIV), type 2 diabetes mellitus and disorders of glucose metabolism have emerged as an important issue in the care of this population. Multiple mechanisms, both specific and nonspecific to HIV, underlie a significant prevalence. Although best-practice diagnostic testing remains unclear, the risks associated with diabetes in the setting of HIV are well characterized, ranging from organ-specific damage to socioeconomic decline. As population-specific treatment data are limited, current guidelines serve as a basis for ongoing management.

Indexed as

AnimalsDiabetes Mellitus, Type 2HIV-1HIV InfectionsHumansCardiovascular diseaseCombination antiretroviral therapyDiabetesDisorders of glucose metabolismHuman immunodeficiency virus

Identifiers

PMID25169561
PMCPMC4159723

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.